Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also
referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of
patients with advanced clear cell renal cell carcinoma (ccRCC).